Qternmet XR (Dapagliflozin, Saxagliptin, and Metformin Hydrochloride) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 8, 2019 Category: Drugs & Pharmacology Source Type: news

Qternmet XR Combinations Approved for Type-2 Diabetes
New drug combines dapagliflozin, saxagliptin, and metformin. (Source: ConsultantLive)
Source: ConsultantLive - May 6, 2019 Category: Internal Medicine Authors: Drew Boxler Tags: Diabetes Diabetes Type 2 Latest e-News New Products The Latest Source Type: news

FDA Approves Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) for Type 2 Diabetes
 3 May 2019 -- The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 3, 2019 Category: Drugs & Pharmacology Source Type: news

Dapagliflozin Improves Glucose Outcomes in Type 1 Diabetes
FRIDAY, April 26, 2019 -- In patients with type 1 diabetes, treatment with dapagliflozin for 24 weeks improves time in range, mean glucose, and glycemic variability, according to a study published online April 9 in Diabetes Care. Chantal Mathieu,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2019 Category: Pharmaceuticals Source Type: news

Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF
Survivals gains were seen in DECLARE-TIMI 58 only in those with low ejection fractions. Preliminary, but it suggests an SGLT2 inhibitor benefit in a range of people with diabetes and heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 4, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Forxiga approved in Japan for type-1 diabetes
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). The approval is based on data from the Phase III DEPICT clinical programme and a dedicated trial in Japanese patients (D1695C00001). (Source: World Pharma News)
Source: World Pharma News - March 27, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

ACC.19: 3 Studies in Cardioprotection
Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA. (Source: ConsultantLive)
Source: ConsultantLive - March 25, 2019 Category: Internal Medicine Authors: Veronica Hackethal, MD Tags: Cardiovascular Disease Source Type: news

EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes
British drugmaker AstraZeneca Plc said on Monday the European Commission approved its diabetes drug Forxiga for use as an oral supplement to insulin in adults with a rare type of the disease. (Source: Reuters: Health)
Source: Reuters: Health - March 25, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Diabetes drug effective against heart failure in wide spectrum of patients
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction, a measure of the heart's pumping ability indicative of poor heart functioning, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (Source: World Pharma News)
Source: World Pharma News - March 18, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA Approves Expanded Uses for Type 2 Diabetes Drugs FDA Approves Expanded Uses for Type 2 Diabetes Drugs
Dapagliflozin has been okayed for patients with moderate renal impairment, and single-injection GLP-1 agonist/basal insulin combos Soliqua and Xultophy are now approved for earlier intensification of therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Go ahead for first add-on tablet to insulin treatment for type 1 diabetes
European regulator recommends dapagliflozin for those with poor blood glucose control despite best efforts Related items fromOnMedica Use of DPP-4 inhibitors associated with increased risk of IBD Adding insulin to metformin linked to higher mortality Draft diabetes guidance too heavily focused on cost, protests industry MHRA tightens licence restrictions on valproate for women Withdrawn valsartan meds not linked to short-term cancer risk (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 5, 2019 Category: UK Health Source Type: news

Forxiga receives positive EU CHMP opinion for the treatment of adults with type-1 diabetes
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxiga (dapagliflozin), after adopting a positive opinion for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D). (Source: World Pharma News)
Source: World Pharma News - February 4, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

EU Panel Backs Dapagliflozin for Some With Type 1 Diabetes EU Panel Backs Dapagliflozin for Some With Type 1 Diabetes
If approved, it would be the first oral add-on to insulin worldwide, but could only be used in patients in whom risk of diabetic ketoacidosis can be properly mitigated.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Harms of Treatment; Height and Longevity: It's PodMed Double T! (with audio)
(MedPage Today) -- This week's topics also include when to start a common Parkinson's disease drug and dapagliflozin's effects on heart risks (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 26, 2019 Category: Cardiology Source Type: news

Effect of Dapagliflozin in T2D Patients With Stages 3b-4 CKD Effect of Dapagliflozin in T2D Patients With Stages 3b-4 CKD
Is dapagliflozin an effective therapeutic option for patients with type 2 diabetes and chronic kidney disease? How does it impact clinical outcomes in these patients?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 22, 2018 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM
TUESDAY, Nov. 13, 2018 -- Treatment with dapagliflozin is noninferior to placebo for major adverse cardiovascular events (MACE) among patients with type 2 diabetes with or at risk for atherosclerotic cardiovascular disease, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 13, 2018 Category: Pharmaceuticals Source Type: news

AHA: Mixed Results with Dapagliflozin in T2D Patients
(MedPage Today) -- SGLT2 inhibitor didn't change MACE rate, but did result in other positive CV outcomes (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 10, 2018 Category: Cardiology Source Type: news

DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes
The trial did not show a significant reduction in major adverse cardiovascular events but does extend the heart failure benefits of SGLT2 inhibitors to the primary prevention population.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Diabetes Drug, Farxiga, Might Also Ease Heart Failure Risks
SATURDAY, Nov. 10, 2018 -- The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows. Type 2 diabetics who took Farxiga (dapagliflozin) saw their odds of hospitalization for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 10, 2018 Category: General Medicine Source Type: news

Diabetes Drug Farxiga (dapagliflozin) Might Also Ease Heart Failure Risks
SATURDAY, Nov. 10, 2018 -- The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows. Type 2 diabetics who took Farxiga (dapagliflozin) saw their odds of hospitalization for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 10, 2018 Category: General Medicine Source Type: news

Diabetes Drug Might Also Ease Heart Failure Risks
SATURDAY, Nov. 10, 2018 -- The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows. Type 2 diabetics who took Farxiga (dapagliflozin) saw their odds of hospitalization for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 10, 2018 Category: General Medicine Source Type: news

Dapagliflozin CV Outcomes; New Guideline on Congenital Adrenal Hyperplasia
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - September 28, 2018 Category: Pediatrics Source Type: news

DECLARE-TIMI 58: HF Benefit for Dapagliflozin in Diabetes? DECLARE-TIMI 58: HF Benefit for Dapagliflozin in Diabetes?
Top-line data from DECLARE-TIMI 58 hint that CV benefit of the SGLT2 inhibitor dapagliflozin for type 2 diabetes is driven by improvement in heart failure, but 60% of patients were primary prevention.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

How One Class Of Diabetes Medications May Lead To Flesh-Eating Genital Infections
If you are taking canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, or any other sodium-glucose cotransporter-2 (SGLT2) inhibitor, you may want to pay attention to this FDA warning. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 1, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

Incretin/SGLT-2 Combo Efficacy Persists 2 Years
(MedPage Today) -- Exenatide plus dapagliflozin maintained biomarker benefits in long-term study (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 26, 2018 Category: Cardiology Source Type: news

Dapagliflozin Tied to Drop in Hepcidin Levels
(MedPage Today) -- Decrease may boost hematocrit and hemoglobin after SGLT-2 inhibitor therapy (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - May 20, 2018 Category: Urology & Nephrology Source Type: news

Real-World Study Shows INVOKANA ® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 27, 2018 Category: Pharmaceuticals Source Type: news

New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors
AstraZeneca has announced results from a new analysis of its landmark CVD-REAL study, the first large real-world evidence study of its kind evaluating the risk of all-cause death (ACD), hospitalisation for heart failure (hHF), heart attack (myocardial infarction or MI) and stroke in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i), including Farxiga (dapagliflozin) versus other glucose-lowering medicines. (Source: World Pharma News)
Source: World Pharma News - March 14, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Dapagliflozin:'Helpful Strategy' for T1D? Dapagliflozin:'Helpful Strategy' for T1D?
Research presented at EASD 2017 shows that dapagliflozin may reduce insulin requirements with a low risk of adverse effects in patients with type 1 diabetes.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 20, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Type 2 Diabetes Drug Improves Glycemic Control in Type 1 Diabetes (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS The type 2 diabetes drug dapagliflozin helps improve glycemic control when added to insulin therapy in patients with type 1 diabetes, according to an … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 15, 2017 Category: Primary Care Source Type: news

Another SGLT2 Drug Shines as Insulin Adjunct in T1D (CME/CE)
(MedPage Today) -- Dapagliflozin lowered HbA1c in phase III trial (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 14, 2017 Category: Cardiology Source Type: news

DEPICT-1: Dapagliflozin Works in T1D With Little Ketoacidosis DEPICT-1: Dapagliflozin Works in T1D With Little Ketoacidosis
Dapagliflozin provided significant reductions in HbA1c, total daily insulin dose, and body weight in type 1 diabetes and was well tolerated, with no new safety signals, in a 24-week trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients
(University at Buffalo) A majority of patients with type 1 diabetes who were treated with dapagliflozin, a type 2 diabetes medicine, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes and Endocrinology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2017 Category: International Medicine & Public Health Source Type: news

dapagliflozin, Farxiga
Title: dapagliflozin, FarxigaCategory: MedicationsCreated: 12/1/2014 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - August 8, 2017 Category: Endocrinology Source Type: news

Qtern (dapagliflozin and saxagliptin) for the Treatment of Type 2 Diabetes
Qtern (dapagliflozin and saxagliptin) is a combination drug with sodium/glucose cotransporter (SGLT) 2 and dipeptidyl peptidase 4 (DPP-4) inhibitors indicated for the treatment of type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - March 9, 2017 Category: Pharmaceuticals Source Type: news

Qtern (Dapagliflozin and Saxagliptin Tablets, for Oral Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 8, 2017 Category: Drugs & Pharmacology Source Type: news

Qtern (Dapagliflozin and Saxagliptin Tablets, for Oral Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 8, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Finally OKs Dapagliflozin/Saxagliptin for Type 2 Diabetes FDA Finally OKs Dapagliflozin/Saxagliptin for Type 2 Diabetes
After first rejecting it at the end of 2015, the FDA has now approved the AstraZeneca DPP-4 inhibitor/SGLT2 inhibitor fixed-dose combination product Qtern for type 2 diabetes in adults.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 28, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes. The new medicine is indicated as an adjunct to diet and exercise to improve glycaemic (blood sugar level) control in adults with type-2 diabetes who have inadequate control with dapagliflozin (10mg) or who are already treated with dapagliflozin and saxagliptin. (Source: World Pharma News)
Source: World Pharma News - February 28, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

FDA Approves Once-Daily Qtern (dapagliflozin and saxagliptin) Tablets for Adults with Type-2 Diabetes
28 February 2017 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes. The new medicine is indicated as an adjunct... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2017 Category: Drugs & Pharmacology Source Type: news

Monthly News Roundup - February 2017
FDA Approves Once-Daily Qtern Tablets for Adults with Type 2 Diabetes The U.S. Food and Drug Administration (FDA) has cleared AstraZeneca’s Qtern (dapagliflozin and saxagliptin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2017 Category: Pharmaceuticals Source Type: news

AstraZeneca announces availability of saxa / dapa FDC in UK
UK-based AstraZeneca has announced the availability of Qtern (saxagliptin and dapagliflozin fixed-dose combination) for adult patients with type 2 diabetes. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 27, 2017 Category: Pharmaceuticals Source Type: news

NICE recommends dapagliflozin for T2DM triple therapy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2016 Category: Drugs & Pharmacology Source Type: news

NICE approves extra ‘triple therapy’ drug for diabetes
Regulator recommends dapagliflozin in triple therapy Related items fromOnMedica Glycosylated haemoglobin (HbA1c) and screening for diabetes Diabetes drugs costs NHS England nearly £1bn a year Intensive treatment of type 2 diabetes with microalbuminuria reaps benefits NICE guidance delays hinder good diabetes care Diabetes prescriptions rise by a third in last five years (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 24, 2016 Category: UK Health Source Type: news

NICE looks set to back ‘triple therapy’ diabetes drug
The National Institute for Health and Care Excellence has provisionally recommended dapagliflozin for treating type 2 diabetes in “triple therapy”. (Source: Nursing Times)
Source: Nursing Times - October 7, 2016 Category: Nursing Source Type: news

First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes
Exenatide once weekly combined with daily dapagliflozin improved glycemic outcomes, BP, and weight loss more than each drug alone in DURATION-8, the first trial to examine a combination of these 2 agents.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 20, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Triple Therapy in Type 1 Diabetes Improves Glycemic Control but Carries Ketosis Risks (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Adding dapagliflozin to liraglutide and insulin in patients with type 1 diabetes lowers hemoglobin A1c levels but poses risk for ketoacidosis, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 5, 2016 Category: Primary Care Source Type: news

Triple therapy helped type 1 patients improve glycemia
NEW ORLEANS – The addition of dapagliflozin to insulin and liraglutide in patients with type 1 diabetes resulted in a significant improvement in glycemia, results from a single-center randomized... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 13, 2016 Category: Endocrinology Source Type: news

Farxiga (Dapagliflozin Film-coated Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 28, 2016 Category: Drugs & Pharmacology Source Type: news

Xigduo XR (Dapagliflozin and Metformin HCl Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 27, 2016 Category: Drugs & Pharmacology Source Type: news